
|Videos|July 19, 2016
Charles Ryan, MD: Comparison of Chemotherapy to a Secondary Hormone at the Time of Progression
Advertisement
Episodes in this series

At the time of progression, would you go back to chemotherapy or use a secondary hormone?
CASE: Metastatic Prostate Cancer (Part 2)
Mathew J is a 61 year old African American male who presented to his primary care physician with lower urinary tract symptoms, including sporadic hematuria. He complains of abdominal pain and low back pain starting four months ago and increasing in frequency. Prior medical history includes non-insulin dependent diabetes mellitus, well-controlled on metformin since 2006. The patient was referred to urology for further evaluation. ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
- Digital rectum exam revealed nodular prostate /L
- Serum PSA level; 129 ng/ml
- Alkaline phosphatase, 258
- TRUS/prostate biopsy: 53 gram prostate, 12/12 cores (+), Gleason 4 + 5
- CT indicates blastic lesions to lumbar spine and pelvis
- Bone Scan positive for T/L spine, pelvis, right femur, scapula
- ECOG performance status, 1
Advertisement
Related to this article

Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.

NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
4
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
5










